S&P 500   4,692.41 (+0.12%)
DOW   35,691.29 (-0.08%)
QQQ   398.69 (+0.22%)
AAPL   174.29 (+1.82%)
MSFT   332.37 (-0.76%)
FB   330.46 (+2.37%)
GOOGL   2,939.89 (-0.19%)
AMZN   3,522.13 (-0.03%)
TSLA   1,061.61 (+0.94%)
NVDA   318.11 (-1.90%)
BABA   126.06 (+0.41%)
NIO   35.00 (+5.68%)
CGC   11.04 (+3.76%)
AMD   144.75 (-0.07%)
GE   98.37 (+0.84%)
MU   85.83 (+0.00%)
T   23.22 (+0.61%)
F   19.84 (-0.60%)
DIS   153.51 (+1.79%)
PFE   51.47 (-0.48%)
AMC   32.69 (+5.32%)
ACB   6.65 (+4.23%)
BA   211.11 (+1.09%)
S&P 500   4,692.41 (+0.12%)
DOW   35,691.29 (-0.08%)
QQQ   398.69 (+0.22%)
AAPL   174.29 (+1.82%)
MSFT   332.37 (-0.76%)
FB   330.46 (+2.37%)
GOOGL   2,939.89 (-0.19%)
AMZN   3,522.13 (-0.03%)
TSLA   1,061.61 (+0.94%)
NVDA   318.11 (-1.90%)
BABA   126.06 (+0.41%)
NIO   35.00 (+5.68%)
CGC   11.04 (+3.76%)
AMD   144.75 (-0.07%)
GE   98.37 (+0.84%)
MU   85.83 (+0.00%)
T   23.22 (+0.61%)
F   19.84 (-0.60%)
DIS   153.51 (+1.79%)
PFE   51.47 (-0.48%)
AMC   32.69 (+5.32%)
ACB   6.65 (+4.23%)
BA   211.11 (+1.09%)
S&P 500   4,692.41 (+0.12%)
DOW   35,691.29 (-0.08%)
QQQ   398.69 (+0.22%)
AAPL   174.29 (+1.82%)
MSFT   332.37 (-0.76%)
FB   330.46 (+2.37%)
GOOGL   2,939.89 (-0.19%)
AMZN   3,522.13 (-0.03%)
TSLA   1,061.61 (+0.94%)
NVDA   318.11 (-1.90%)
BABA   126.06 (+0.41%)
NIO   35.00 (+5.68%)
CGC   11.04 (+3.76%)
AMD   144.75 (-0.07%)
GE   98.37 (+0.84%)
MU   85.83 (+0.00%)
T   23.22 (+0.61%)
F   19.84 (-0.60%)
DIS   153.51 (+1.79%)
PFE   51.47 (-0.48%)
AMC   32.69 (+5.32%)
ACB   6.65 (+4.23%)
BA   211.11 (+1.09%)
S&P 500   4,692.41 (+0.12%)
DOW   35,691.29 (-0.08%)
QQQ   398.69 (+0.22%)
AAPL   174.29 (+1.82%)
MSFT   332.37 (-0.76%)
FB   330.46 (+2.37%)
GOOGL   2,939.89 (-0.19%)
AMZN   3,522.13 (-0.03%)
TSLA   1,061.61 (+0.94%)
NVDA   318.11 (-1.90%)
BABA   126.06 (+0.41%)
NIO   35.00 (+5.68%)
CGC   11.04 (+3.76%)
AMD   144.75 (-0.07%)
GE   98.37 (+0.84%)
MU   85.83 (+0.00%)
T   23.22 (+0.61%)
F   19.84 (-0.60%)
DIS   153.51 (+1.79%)
PFE   51.47 (-0.48%)
AMC   32.69 (+5.32%)
ACB   6.65 (+4.23%)
BA   211.11 (+1.09%)
NASDAQ:PSTI

Pluristem Therapeutics Stock Forecast, Price & News

$2.42
+0.02 (+0.83%)
(As of 12/8/2021 01:40 PM ET)
Add
Compare
Today's Range
$2.39
$2.44
50-Day Range
$2.28
$3.10
52-Week Range
$2.22
$11.85
Volume
1,832 shs
Average Volume
410,224 shs
Market Capitalization
$77.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.26
30 days | 90 days | 365 days | Advanced Chart
Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Pluristem Therapeutics logo

About Pluristem Therapeutics

Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Headlines

IceCure Medical Ltd (ICCM.TA)
August 9, 2021 |  ca.finance.yahoo.com
Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS
July 29, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PSTI
Employees
152
Year Founded
2003

Sales & Book Value

Annual Sales
$20 thousand
Book Value
$1.52 per share

Profitability

Net Income
$-49.87 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
30,527,000
Market Cap
$77.68 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/08/2021
Next Earnings (Estimated)
2/14/2022
Fiscal Year End
6/30/2022

Social Links


MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

875th out of 1,394 stocks

Biological Products, Except Diagnostic Industry

134th out of 202 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

Is Pluristem Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pluristem Therapeutics stock.
View analyst ratings for Pluristem Therapeutics
or view top-rated stocks.

How has Pluristem Therapeutics' stock price been impacted by Coronavirus?

Pluristem Therapeutics' stock was trading at $2.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PSTI stock has decreased by 16.3% and is now trading at $2.42.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Pluristem Therapeutics?

Pluristem Therapeutics saw a increase in short interest in October. As of October 29th, there was short interest totaling 426,300 shares, an increase of 31.9% from the October 14th total of 323,100 shares. Based on an average trading volume of 185,900 shares, the short-interest ratio is currently 2.3 days. Currently, 1.5% of the company's stock are short sold.
View Pluristem Therapeutics' Short Interest
.

When is Pluristem Therapeutics' next earnings date?

Pluristem Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for Pluristem Therapeutics
.

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.05.
View Pluristem Therapeutics' earnings history
.

When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work?

Shares of Pluristem Therapeutics reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PSTI?

2 equities research analysts have issued 12-month price targets for Pluristem Therapeutics' shares. Their forecasts range from $6.00 to $12.50. On average, they anticipate Pluristem Therapeutics' stock price to reach $9.25 in the next year. This suggests a possible upside of 282.2% from the stock's current price.
View analysts' price targets for Pluristem Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the following people:
  • Yaky Yanay, President, Chief Executive Officer & Director
  • Lior Raviv, Vice President-Operations & Development
  • Chen Franco-Yehuda, Chief Financial Officer, Secretary & Treasurer
  • Racheli Ofir, Vice President-Research & Intellectual Property
  • Nitsan Halevy, Chief Medical Officer

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Protalix BioTherapeutics (PLX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD).

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

Who are Pluristem Therapeutics' major shareholders?

Pluristem Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nia Impact Advisors LLC (2.28%), Renaissance Technologies LLC (1.21%), GSA Capital Partners LLP (0.80%), Shelton Capital Management (0.75%), Caption Management LLC (0.00%) and Nikko Asset Management Americas Inc. (0.33%).
View institutional ownership trends for Pluristem Therapeutics
.

Which major investors are selling Pluristem Therapeutics stock?

PSTI stock was sold by a variety of institutional investors in the last quarter, including HAP Trading LLC, Jane Street Group LLC, Citadel Advisors LLC, Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., and Nikko Asset Management Americas Inc..
View insider buying and selling activity for Pluristem Therapeutics
or view top insider-selling stocks.

Which major investors are buying Pluristem Therapeutics stock?

PSTI stock was purchased by a variety of institutional investors in the last quarter, including Nia Impact Advisors LLC, GSA Capital Partners LLP, Millennium Management LLC, Shelton Capital Management, Morgan Stanley, TownSquare Capital LLC, Geode Capital Management LLC, and HighTower Advisors LLC.
View insider buying and selling activity for Pluristem Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $2.42.

How much money does Pluristem Therapeutics make?

Pluristem Therapeutics has a market capitalization of $77.68 million and generates $20 thousand in revenue each year.

How many employees does Pluristem Therapeutics have?

Pluristem Therapeutics employs 152 workers across the globe.

When was Pluristem Therapeutics founded?

Pluristem Therapeutics was founded in 2003.

What is Pluristem Therapeutics' official website?

The official website for Pluristem Therapeutics is www.pluristem.com.

Where are Pluristem Therapeutics' headquarters?

Pluristem Therapeutics is headquartered at MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company can be reached via phone at 972747107171, via email at [email protected], or via fax at 972-74-710-8787.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.